Ukraine.UroWeb.ru — Український інформаційний портал урологів
(Украинский информационный портал урологов)

Навигация
Главная
О проекте
О нас
Контакты
Журналы
ЛОКЛ
Новости
Конференции и симпозиумы
Профсоюзы
Реформы и предложения
Обращения
Обучение
Библиотека
Лекции
Нормативные документы
Производители
Ссылки
Наши партнеры

Информация для пациентов

Консультации уролога
Форум
Поиск

Ассоциация урологов Украины
Сайт Института урологии Академии медицинских наук Украины
Европейская Ассоциация Урологов
UroWeb.ru - Урологический информационный портал
Explorer.UroWeb.ru — исследователь урологии
Авторизация


 
Главная arrow Новости
Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo Версия для печати Отправить на e-mail
12.07.2016

Phase III trial finds excellent safety and tolerability

BARCELONA-LUGANO, 02 July 2016 – A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data (1) presented at the European Society for Medical Oncology’s 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralize interleukin-1 alpha (IL-1α), one of the most potent inflammatory substances manufactured by the body or tumour cells.

“IL-1α in tumours promotes angiogenesis, helping to provide crucial blood supply for tumour growth, and it can also send the body’s metabolism out of control, causing it to burn muscle and lose weight,” said lead investigator Dr Tamas Hickish. At the same time, IL-1α effects on the brain can cause the fatigue, anxiety and anorexia associated with advanced cancer.

Продолжение...
 
New jobs in Urology from Elsevier's top journals Версия для печати Отправить на e-mail
12.07.2016

 

eHealthCareers.com Powered by Elsevier
Продолжение...
 
Abstract Submission for London is Open Версия для печати Отправить на e-mail
12.07.2016
 
32nd Annual EAU Congress
 
 
32nd Annual EAU Congress
 
EAU17 Abstract Submission is open
 

Dear Prof. Aleksandr Shulyak,

Europe’s biggest urological event is coming to London next year! From 24 to 28 March 2017, the London ExCel will host the 32nd Annual EAU Congress (EAU17).
 
Preparations are already in full swing and as of today you can contribute to one of the most comprehensive scientific programmes in the field of urology. The EAU17 abstract submission is now open!
 
How to submit your abstract?
You can submit your abstract via the online abstract submission system. Faxed, e-mailed or mailed abstracts will not be accepted. Carefully read the Abstract submission rules and regulations before submitting your abstract.

 
Your last chance to register for EAU16
Продолжение...
 
Regorafenib shows significant survival gains in refractory liver cancer Версия для печати Отправить на e-mail
12.07.2016

Phase III trial confirms efficacy and safety of new second-line agent

BARCELONA-LUGANO, 30 June 2016 – Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial (1), presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

“Systemic treatment for hepatocellular carcinoma has long consisted of just one agent - sorafenib –which was shown to provide a significant improvement in life expectancy almost 10 years ago, but no other agent has surpassed its benefits,” said the study’s principal investigator Dr Jordi Bruix, Head of the BCLC group at the Hospital Clínic and Scientific Director of the Network for Biomedical Research for Hepatic and Digestive Diseases (CIBEREHD).

Продолжение...
 
Anti-PD-L1 immunotherapy shows response in microsatellite-stable metastatic colorectal cancer in combination with MEK inhibition Версия для печати Отправить на e-mail
07.07.2016

BARCELONA-LUGANO, 29 June 2016 – Anti-PD-L1 immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

“So far, immunotherapy has only shown activity in patients with microsatellite instability-high colorectal cancer, which is only 5% of the population,” says the study’s (1) principal investigator Dr Johanna Bendell, from the Sarah Cannon Research Institute and Tennessee Oncology, in Nashville, Tennessee.

Microsatellite instability-high colorectal cancers are associated with a greater number of mutations and are therefore more responsive to immunotherapy with PD-L1/PD-1 blockade. However the majority of patients with metastatic colorectal cancer – around 95% - have microsatellite-stable disease that so far has shown almost no response to immunotherapy.

Продолжение...
 
Еще...
<< В начало < Предыдущая 1 2 3 4 5 6 7 8 Следующая > В конец >>

Всего 211 - 315 из 803
Ukraine.UroWeb.ru - Український інформаційний портал урологів (Украинский информационный портал урологов) © 2018